How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,634 results for

Insomnia Causes

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

2621. Melatonin treatment for age-related insomnia. (PubMed)

Melatonin treatment for age-related insomnia. Older people typically exhibit poor sleep efficiency and reduced nocturnal plasma melatonin levels. The daytime administration of oral melatonin to younger people, in doses that raise their plasma melatonin levels to the nocturnal range, can accelerate sleep onset. We examined the ability of similar, physiological doses to restore nighttime melatonin levels and sleep efficiency in insomniac subjects over 50 yr old. In a double-blind, placebo (...) in the midthird of the night; it also elevated plasma melatonin levels (P < 0.0008) to normal. The pharmacologic dose (3.0 mg), like the lowest dose (0.1 mg), also improved sleep; however, it induced hypothermia and caused plasma melatonin to remain elevated into the daylight hours. Although control subjects, like insomniacs, had low melatonin levels, their sleep was unaffected by any melatonin dose.

Full Text available with Trip Pro

2001 The Journal of clinical endocrinology and metabolism

2622. Health-related quality of life in patients with insomnia treated with zopiclone. (PubMed)

Health-related quality of life in patients with insomnia treated with zopiclone. Insomnia can cause impaired productivity and absenteeism from work, increased risk of accidents, and impaired quality of family and social life. Thus, it can compromise quality of life in affected individuals and result in costs to society as a whole. The nonbenzodiazepine hypnotic zopiclone is effective and well tolerated in the treatment of insomnia. Importantly, it also has minimal effects on next-day (...) patients who had been taking zopiclone for at least 12 months and a control group of 381 persons with no sleep problems in virtually all of the 5 aspects of the quality-of-life questionnaire. Some important aspects such as relationships and professional life were not modified by zopiclone. When insomnia is treated appropriately, compared with no treatment, patients' feelings about their quality of life are improved and, furthermore, do not appear to differ significantly from perceptions of quality

1996 PharmacoEconomics

2623. Magnesium therapy for periodic leg movements-related insomnia and restless legs syndrome: an open pilot study. (PubMed)

Magnesium therapy for periodic leg movements-related insomnia and restless legs syndrome: an open pilot study. Periodic limb movements during sleep (PLMS), with or without symptoms of a restless legs syndrome (RLS), may cause sleep disturbances. The pharmacologic treatments of choice are dopaminergic drugs. Their use, however, may be limited due to tolerance development or rebound phenomena. Anecdotal observations have shown that oral magnesium therapy may ameliorate symptoms in patients (...) with moderate RLS. We report on an open clinical and polysomnographic study in 10 patients (mean age 57 +/- 9 years; 6 men, 4 women) suffering from insomnia related to PLMS (n = 4) or mild-to-moderate RLS (n = 6). Magnesium was administered orally at a dose of 12.4 mmol in the evening over a period of 4-6 weeks. Following magnesium treatment, PLMS associated with arousals (PLMS-A) decreased significantly (17 +/- 7 vs 7 +/- 7 events per hour of total sleep time, p < 0.05). PLMS without arousal were also

1998 Sleep

2624. Insomnia in general practice: the role of temazepam and a comparison with zopiclone. (PubMed)

Insomnia in general practice: the role of temazepam and a comparison with zopiclone. The aetiology of insomnia can be conveniently divided into six groups: physical (pain, cough, etc.), physiological (shift-workers etc.), psychological (life events), psychiatric (depression, anxiety, etc.), iatrogenic (stimulant drugs, etc.) and idiopathic (no obvious cause). The four main types of insomnia are: prolonged latency, frequent short awakenings, one or two long awakenings and early morning awakening

1986 Acta psychiatrica Scandinavica. Supplementum

2625. Comparative study of midazolam and vesparax in moderate or severe insomnia in female surgical patients. (PubMed)

Comparative study of midazolam and vesparax in moderate or severe insomnia in female surgical patients. A double-blind study was conducted in 60 female patients with moderate or severe insomnia, hospitalized for gynaecological surgery. After an initial 2-day placebo selection phase, 30 subjects received 15 mg midazolam and the remaining 30 received 1 tablet Vesparax (= 50 mg hydroxyzine, 150 mg secobarbital, 50 mg brallobarbital) for 5 nights. This verum phase was immediately followed by a 2 (...) -day placebo withdrawal phase in order to study the occurrence of rebound phenomena. Both verum compounds were effective in hastening sleep onset, increasing sleep duration, and improving sleep quality, without causing residual effects on the following day. There was no difference in effect between the two agents. Neither active drug caused rebound effects on withdrawal.

Full Text available with Trip Pro

1983 British journal of clinical pharmacology

2626. Insomnia during the "dark period" in northern Norway. An explorative, controlled trial with light treatment. (PubMed)

Insomnia during the "dark period" in northern Norway. An explorative, controlled trial with light treatment. Midwinter insomnia (MI) is an initial type insomnia that is typically seen north of the Polar Circle during the "dark period", when the sun does not rise above the horizon. The cause of MI is not known, but it seems reasonable to assume that it is the expression of a phase delay of the sleep-wake cycle, due to lack of the entraining effect of normal daylight. Based on his hypothesis, we

1985 Acta Psychiatrica Scandinavica

2627. Flurazepam and temazepam in the treatment of insomnia in a general hospital population. (PubMed)

Flurazepam and temazepam in the treatment of insomnia in a general hospital population. This study is a double-blind comparative trial of flurazepam and temazepam in the treatment of insomnia, using subjective assessments with an analogue scale technique and questionnaire. The main dependent variable in this experiment is vigilance. The two drugs differ essentially in their half life value. (Flurazepam +/- 72 h; temazepam +/- 8 h). It can be predicted that temazepam causes less impairment

1984 Pharmacopsychiatry

2628. A clinical study of quazepam in hospitalized patients with insomnia. (PubMed)

A clinical study of quazepam in hospitalized patients with insomnia. The efficacy of quazepam (Sch-16134) 15 mg capsules as a hypnotic has been compared with that of placebo in a 9-day study, using a parallel-group design. The physician's global evaluation numerically favoured quazepam 63% (nineteen of thirty) over placebo 50% (fifteen of thirty). Furthermore, it demonstrated greater improvement in Hypnotic Activity Index and Sleep Quality Index from baseline scores, and caused no adverse

1981 The Journal of international medical research

2629. Short-term quazepam treatment of insomnia in geriatric patients. (PubMed)

Short-term quazepam treatment of insomnia in geriatric patients. The efficacy and safety of 15 mg quazepam was compared with placebo in 57 geriatric outpatients with insomnia. The study was double-blind, with treatments randomly assigned to patients. Placebo was taken by all patients for the first 3 nights followed by either placebo or quazepam for 5 nights. Post-sleep questionnaires were completed each day and the physician and patients rated the treatment at the end of the study. Quazepam (...) was significantly better than placebo on all measures of efficacy. Indices of sleep quantity and quality showed that 15 mg quazepam produced significantly greater improvement in sleep than placebo on the first night of treatment and for the treatment period as a whole. There were no reports of unexpected or serious adverse experiences, and quazepam did not cause ataxia or impairment of motor co-ordination in any patient.

1982 Pharmatherapeutica

2630. Model insomnia by methylphenidate and caffeine and use in the evaluation of temazepam. (PubMed)

Model insomnia by methylphenidate and caffeine and use in the evaluation of temazepam. Experimental sleep disturbances (model insomnia) were produced by the administration of methylphenidate (MPD) 10 mg and caffeine (CAF) 150 mg. The effect of temazepam (TEM), 15 mg or 30 mg, on the model was investigated. All-night polysomnography was performed on 8 normal young male subjects under each of the following 9 conditions: baseline, MPD 10 mg, CAF 150 mg, TEM 15 mg, TEM 30 mg, MPD + TEM 15 mg, MPD (...) + TEM 30 mg, CAF + TEM 15 mg, CAF + TEM 30 mg. A reduction in total sleep time and total amount of stage REM (S-REM) sleep and an increase in the sleep latency and wake time (S-W) were observed in both the MPD and CAF nights. The sleep latency was significantly longer in the CAF night than in the MPD night. Administration of TEM 15 mg or TEM 30 mg alone caused very few modifications in the sleep parameters. These drugs in combination with MPD or CAF resulted in almost complete recovery of the sleep

1982 Psychopharmacology

2631. Insomnia and sleep disruption: relevance for athletic performance. (PubMed)

Insomnia and sleep disruption: relevance for athletic performance. Insomnia is a common sleep complaint even in young adults and has important daytime consequences. Several subjective and objective tools are recommended to assess the magnitude of the problem and to try to find a cause. Chronic insomnia is often caused by precipitating factors, such as acute stress, work conditions, illness, and travel, and perpetuating factors, such as poor sleep hygiene, anxiety, and medications. Insomnia may (...) have implications in athletic performance resulting from physical and cognitive effects. Several pharmacologic and nonpharmacologic approaches are employed in the management of insomnia that have proven effective for short-term treatment. The pharmacologic approaches include the use of zolpidem and specific GABA agonists, benzodiazepines for specific indications, antidepressants, and melatonin. The nonpharmacologic approaches include stimulus control, sleep restriction, relaxation strategies

2005 Clinics in Sports Medicine

2632. Can taking thyroxine tablets in the evening instead of the morning cause insomnia?

Can taking thyroxine tablets in the evening instead of the morning cause insomnia? Can taking thyroxine tablets in the evening instead of the morning cause insomnia? - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing (...) including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Can taking thyroxine tablets in the evening instead of the morning cause insomnia? A search of medline found no articles that might answer this question. The patient information leaflet for levothyroxine tablet [1] reports

2006 TRIP Answers

2633. Insomnia in the elderly: cause, approach, and treatment. (PubMed)

Insomnia in the elderly: cause, approach, and treatment. Insomnia is a prevalent problem in late life. Sleep problems in the elderly are often mistakenly considered a normal part of aging. Insomnia, the most common sleep disorder, is a subjective report of insufficient or nonrestorative sleep despite adequate opportunity to sleep. Despite the fact that more than 50% of elderly people have insomnia, it is typically undertreated, and nonpharmacologic interventions are underused by health care (...) practitioners. This article will review the causes of insomnia in the elderly, the approach to patient evaluation, and the nonpharmacologic and pharmacologic treatment of insomnia.

2006 American Journal of Medicine

2634. Zaleplon, A Novel Nonbenzodiazepine Hypnotic, Effectively Treats Insomnia in Elderly Patients Without Causing Rebound Effects. (PubMed)

Zaleplon, A Novel Nonbenzodiazepine Hypnotic, Effectively Treats Insomnia in Elderly Patients Without Causing Rebound Effects. BACKGROUND: Insomnia is a very common symptom, particularly in the elderly. Thus, all hypnotic medications should be carefully evaluated in the elderly population. Zaleplon, a new nonbenzodiazepine hypnotic with a short elimination half-life (approximately 1 hour), was evaluated in the current study. METHOD: This multicenter, randomized, placebo-controlled outpatient (...) study evaluated the efficacy and safety of zaleplon, 5 and 10 mg, in elderly patients with insomnia (as defined by DSM-IV); zolpidem, 5 mg, was the active comparator. Sleep was assessed in 549 elderly patients (>/= 65 years old) by using morning questionnaires completed after each of 7 baseline nights during which placebo was given, 14 nights of double-blind treatment, and 7 nights of placebo after discontinuation of active treatment. RESULTS: Zaleplon, 10 mg, and zolpidem, 5 mg, significantly

Full Text available with Trip Pro

1999 Primary care companion to the Journal of clinical psychiatry

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>